Con­tentious leg­is­la­tion that would clamp down on biotech and phar­ma deals in Chi­na has been in­tro­duced in the Sen­ate, tak­ing the ba­ton from law­mak­ers in...

The FDA will host an ad­vi­so­ry com­mit­tee meet­ing in Sep­tem­ber to re­view Grail's con­tro­ver­sial can­cer test that failed to meet the pri­ma­ry end­point of a...

Chi­na’s rapid ad­vance in biotech will slow as com­pa­nies there be­gin to ex­per­i­ment on the cut­ting edge of R&D, ac­cord­ing to Pfiz­er’s An­drew Baum, who...

A can­cer biotech vy­ing for a piece of As­traZeneca's can­cer ter­ri­to­ry and a pain spe­cial­ist chas­ing Ver­tex's land­mark non-opi­oid drug are cap­ping an IPO-heavy week...

→ One of the most in­flu­en­tial phar­ma ex­ecs at John­son & John­son is re­tir­ing. Jen­nifer Taubert, the world­wide chair of John­son & John­son In­no­v­a­tive...